Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma.
Significant advances in the treatment of melanoma have been made with BRAF-targeted therapy and immune checkpoint blockade, and these strategies are now being combined empirically in clinical trials. Potential synergy is demonstrated in murine models and in analysis of longitudinal biopsies from patients on trial, however important questions remain regarding toxicity, optimal timing and sequence of therapy.
Division of Surgical Oncology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA ; Genomic Medicine; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
Zachary A
ZA
Cooper
Division of Surgical Oncology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
Alexandre
A
Reuben
Department of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
Rodabe N
RN
Amaria
Division of Surgical Oncology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA ; Genomic Medicine; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
Jennifer A
JA
Wargo
 BRAF; PD-1; PD-L1; immune checkpoint; melanoma